Therapy target
Improvement of the symptomatology
Therapy recommendations
- Elimination of the diagnostically identified noxious agent (causative pollutant).
- Symptomatic therapy (preferably local therapy; this must be oriented to the skin condition).
- Topical glucocorticoids (agent of first choice)Note: When using glucocorticoids for > 6 weeks → control and review due topossible adverse drug reactions.
- Tanning agents/tar preparations can be used in addition.
- Topical calcineurin inhibitors (off-label use/use outside the indication areas or the group of people for which the drugs are approved by the drug authorities): in sensitive skin areas such as the face or intertrigines (skin areas in the armpit, in the groin region, in the back of the knee, among others) advantageous due tolack of atrophy risk.
- Antiseptics (agents that are directed against germs) in microbial colonization.
- UVB or PUVA therapy may be considered in chronic eczema (collective term for inflammatory changes of the skin), especially if no noxious agent can be found or eliminated.
- In therapy resistance of hand eczema, therapy with ciclosporin (cyclosporin A) (“off-label use”), azathioprine (“off-label use”) and MTX (“off-label use”) can be considered
- See also under “Other therapy.”
Further notes
- Alitretinoin has the following side effect, among others: hair frizz.
